Evidence map›Paper›PMID 37240128›Full record

ArticleInternational journal of molecular sciences2023

Drug Potency Prediction of SARS-CoV-2 Main Protease Inhibitors Based on a Graph Generative Model.

Sarah Fadlallah, Carme Julià, Santiago García-Vallvé, Gerard Pujadas, Francesc Serratosa

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah FadlallahResearch Group ASCLEPIUS: Smart Technology for Smart Healthcare, Departament d'Enginyeria Informàtica i Matemàtiques, Universitat Rovira i Virgili, 43007 Tarragona, Spain.ORCID 0000-0003-0758-5913
Carme JuliàResearch Group ASCLEPIUS: Smart Technology for Smart Healthcare, Departament d'Enginyeria Informàtica i Matemàtiques, Universitat Rovira i Virgili, 43007 Tarragona, Spain.ORCID 0000-0003-3440-6175
Santiago García-VallvéResearch Group in Cheminformatics and Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43007 Tarragona, Spain.ORCID 0000-0002-0348-7497
Gerard PujadasResearch Group in Cheminformatics and Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43007 Tarragona, Spain.ORCID 0000-0003-2598-8089
Francesc SerratosaResearch Group ASCLEPIUS: Smart Technology for Smart Healthcare, Departament d'Enginyeria Informàtica i Matemàtiques, Universitat Rovira i Virgili, 43007 Tarragona, Spain.ORCID 0000-0001-6112-5913

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prediction of a ligand potency to inhibit SARS-CoV-2 main protease (M-pro) would be a highly helpful addition to a virtual screening process. The most potent compounds might then be the focus of further efforts to experimentally validate their potency and improve them. A computational method to predict drug potency, which is based on three main steps, is defined: (1) defining the drug and protein in only one 3D structure; (2) applying graph autoencoder techniques with the aim of generating a latent vector; and (3) using a classical fitting model to the latent vector to predict the potency of the drug. Experiments in a database of 160 drug-M-pro pairs, from which the pIC50 is known, show the ability of our method to predict their drug potency with high accuracy. Moreover, the time spent to compute the pIC50 of the whole database is only some seconds, using a current personal computer. Thus, it can be concluded that a computational tool that predicts, with high reliability, the pIC50 in a cheap and fast way is achieved. This tool, which can be used to prioritize which virtual screening hits, will be further examined in vitro.

Indexed as

COVID-19Antiviral AgentsCoronavirus 3C ProteasesHumansMolecular Docking SimulationProtease InhibitorsReproducibility of ResultsSARS-CoV-23C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitorsdruggraph autoencodersgraph convolutional networksgraph regressionmolecular descriptorsmolecular potencyneural networkspredictionSARS-CoV-2virtual screening

Identifiers

PMID37240128
PMCPMC10218534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.